Nikolas Hallberg Thuesen
Seminars
Thursday 23rd July 2026
Harnessing Multi-Omics In AI-Immunology™ For Developing Shared Cancer Vaccines Targeting Endogenous Retroviruses
3:30 pm
- Endogenous retroviruses – a novel antigen source which is promising for cancer vaccines
- The development of an ERV targeting cancer vaccine using Evaxion’s AI-Immunology™ platform
- Preclinical validation of an ERV hotspot vaccine which leads to tumor control and T-cell responses
